Business Context and Reporting Period
Company: Laboratory Corporation of America Holdings (LabCorp)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Industry: Independent Clinical Laboratory Services
LabCorp is the second-largest independent clinical laboratory company in the United States. The company operates a national network of 36 primary laboratories and over 1,700 service sites, employing over 25,000 people. Its business model focuses on routine testing, genomic and esoteric testing, and specialty services (oncology, HIV, genetics). A significant strategic development in 2006 was the signing of a ten-year exclusive national laboratory agreement with UnitedHealthcare, effective January 1, 2007.
Key Financial Metrics (Year Ended Dec 31, 2006)
| Metric | 2006 Value | 2005 Value |
|---|---|---|
| Net Sales | $3,590.8 million | $3,327.6 million |
| Gross Profit | $1,529.4 million | $1,390.3 million |
| Operating Income | $697.1 million | $618.1 million |
| Net Earnings | $431.6 million | $386.2 million |
| Diluted EPS | $3.24 | $2.71 |
| Cash from Operations | $632.3 million | $574.2 million |
| Total Assets | $4,000.8 million | $3,875.8 million |
| Long-term Debt | $1,157.4 million | $1,148.9 million |
| Shareholders' Equity | $1,977.1 million | $1,885.7 million |
Margins: Gross margin improved to 42.6% in 2006 from 41.8% in 2005. Operating margin was 19.4% in 2006 compared to 18.6% in 2005.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7.9% year-over-year, driven by a shift in test mix toward higher-priced genomic and esoteric tests (which grew 10.0%) and improved pricing in routine testing.
- Cost of Sales: Increased 6.4% to $2,061.4 million, primarily due to volume growth and $14 million in costs incurred in Q4 2006 to expand patient service delivery capabilities for the UnitedHealthcare contract.
- SG&A Expenses: Increased 10.7% to $779.1 million. This increase was largely due to the adoption of SFAS 123(R) requiring stock-based compensation expense recognition ($23.3 million) and charges related to the CEO's retirement ($12.4 million).
- Interest Expense: Rose 39.0% to $47.8 million, driven by the issuance of $250 million in 5 5/8% senior notes due 2015 in December 2005.
- Special Charges: 2006 included $1.0 million in restructuring charges. In contrast, 2005 included $16.9 million in charges related to the integration of Esoterix and US LABS acquisitions and hurricane relief.
Guidance, Outlook, and Risks
Outlook and Strategy:
- UnitedHealthcare Contract: The company expects to realize over $3 billion in additional revenues from the new exclusive agreement with UnitedHealthcare over the contract term. To support this, the company opened over 400 new patient access points and hired 1,200 employees in anticipation of the 2007 start date.
- Capital Expenditures: Expected to range between $130 million and $170 million in 2007, including investments related to the UnitedHealthcare contract.
- Scientific Differentiation: Continued focus on expanding leadership in genomic and advanced testing technologies through internal development and acquisitions.
Risks and Contingencies:
- Reimbursement Pressure: Significant risk of reduced reimbursement rates from Medicare, Medicaid, and private payers. The company notes that Medicare fee schedules are subject to freezes and reductions.
- Regulatory Compliance: Extensive regulation under CLIA, HIPAA, and anti-fraud/abuse laws. Violations could result in fines, exclusion from government programs, or loss of licensure.
- Legal Proceedings: The company is involved in various claims, including patent disputes (a $7.8 million judgment was paid regarding a patent case, though the company does not expect material adverse effects from remaining proceedings) and qui tam suits under the False Claims Act.
- Integration Risks: Risks associated with integrating newly acquired businesses and the costs thereof.
Investor Verification Checklist
- UnitedHealthcare Contract Impact: Verify the actual revenue realization and cost structure associated with the new exclusive national laboratory agreement starting in 2007.
- Reimbursement Rates: Monitor legislative and regulatory changes regarding Medicare and Medicaid fee schedules, as these directly impact margins given the company's fixed cost structure.
- Stock-Based Compensation: Review the ongoing impact of SFAS 123(R) adoption on reported earnings and cash flow.
- Days Sales Outstanding (DSO): Monitor DSO levels and bad debt expense, as billing complexity and payer mix changes can significantly affect cash flow.
- Debt Obligations: Track the status of the zero-coupon convertible subordinated notes and the company's ability to manage interest expenses and potential conversion events.